HOME › Press Releases › Plasma Therapy Market worth 297.6 Million USD by 2021
Plasma Therapy Market worth 297.6 Million USD by 2021
The report "Plasma Therapy Market by Type (Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin, Leukocyte-Rich Fibrin), Source (Autologous, Allogenic), Application (Orthopedic, Dermatology, Cardiac Muscle Injury), End User, Region - Global Forecast to 2021", The report provides a detailed overview of drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the plasma therapy market, along with estimates and forecast of the revenue and market share analysis.
Browse 141 market data Tables and 98 Figures spread through 210 Pages and in-depth TOC on "Plasma Therapy Market by Type (Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin, Leukocyte-Rich Fibrin), Source (Autologous, Allogenic), Application (Orthopedic, Dermatology, Cardiac Muscle Injury), End User, Region - Global Forecast to 2021"
Early buyers will receive 10% customization on reports.
The global plasma therapy market is expected to grow from USD 135.6 Million in 2016 to USD 297.6 Million by 2021, at a CAGR of 14.0% from 2016 to 2021. Factors driving the growth of the plasma therapy market include rising incidences of trauma and increasing healthcare expenditure worldwide.
The global plasma therapy market is segmented on the basis of type, source, application, end user, and region. Among all types, the pure PRP segment is estimated to account for the largest share of the global plasma therapy market in 2016. This segment is projected to grow at the highest CAGR from 2016 to 2021. The high growth of the pure PRP segment can be attributed to its high success rate and its antimicrobial effects.
On the basis of source, the plasma therapy market is segmented into autologous and allogenic. The autologous segment is estimated to account for the largest share of the global plasma therapy market in 2016, owing to its safety and effective results. Prevalence of orthopedic disorders such as arthritis and tendinitis has propelled the demand for advanced treatment options. This has further contributed to the growth of the plasma therapy market.
On the basis of application, the plasma therapy market is segmented into dermatology, cardiac muscle injury, dental, nerve injury, and others. The orthopedic segment is further categorized into arthritis, chronic tendinitis, and bone repair & regeneration. Similarly, the dermatology segment is classified into androgenic alopecia and plastic surgery. Among all applications, the dermatology segment is expected to grow at a high CAGR from 2016 to 2021, owing to increase in the adoption of cosmetic procedures and prevalence of dermatological disorders such as androgenic alopecia.
With respect to end user, the plasma therapy market is segmented into hospitals & clinics and research institutes. The hospitals & clinics segment is estimated to account for the largest share of the global plasma therapy market in 2016. Rise in healthcare spending has resulted in the increasing use of platelet-rich plasma therapy (PRP) in hospitals & clinics.
Based on region, the global plasma therapy market is segmented into North America, Europe, Asia-Pacific, and rest of the world (RoW). North America is estimated to account for the largest share of the global plasma therapy market in 2016. This large share is mainly attributed to the increase in aging population and initiatives undertaken by the government to support developments in the field of plasma therapy.
Key players in the global plasma therapy market include BioLife Plasma Services (U.S.), Cambryn Biologics LLC (U.S.), Biotest (Germany), CSL Ltd. (Australia), Grifols International S.A. (Spain), Kedrion S.p.A. (Italy), LFB S.A. (France), Bio Products Laboratory Ltd. (BPL) (U.K.), China Biologic Products, Inc. (China), and Octapharma (Switzerland).
MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India